This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Bristol-Myers Squibb Company
Drug Names(s): BMS-663513, anti-CD137 antibody, Anti-CD137 Urelumab
Description: BMS-663513 is an agonist of the CD137 immune cell regulatory protein. Anti-CD137 was found to polarize the antitumor reactivity of T cells to tumor antigen toward a type 1 response (i.e.,IFN-gamma) and away from a type 2 response (IL-4). The administration of anti-CD137 monoclonal antibodies is being explored as an adjuvant given in combination with dendritic cell based vaccines.
Bristol-Myers Squibb and Ono
In July 2014, Bristol-Myers Squibb and Ono have signed a strategic collaboration agreement to jointly develop and commercialize multiple immunotherapies as single agents and combination regimens.
Under the terms of the agreement, Bristol-Myers Squibb and Ono will jointly develop and commercialize all collaboration products in Japan, South Korea and Taiwan. Development costs and commercial profits will be shared equally when Opdivo is used in combination with any Bristol-Myers Squibb compound (Yervoy, lirilumab, urelumab, BMS-986016). For a Bristol-Myers Squibb compound used as monotherapy, or two Bristol-Myers Squibb compounds used in a combination regimen, Bristol-Myers Squibb will fund the substantial majority of development costs and receive the substantial majority of commercial profits. When Opdivo is used as a single agent, Ono will fund the substantial majority of development costs and receive the substantial majority of...See full deal structure in Biomedtracker
Partners: Ono Pharmaceutical Company, Ltd.
Additional information available to subscribers only: